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Abstract The purpose of this study was to examine
whether atomoxetine plasma concentration predicts atten-
tion-deﬁcit/hyperactivity disorder (ADHD) or oppositional
deﬁant disorder (ODD) response. This post-hoc analysis
assessed the relationship between atomoxetine plasma con-
centration and ADHD and ODD symptoms in patients (with
ADHD and comorbid ODD) aged 6–12 years. Patients were
randomlyassignedtoatomoxetine1.2 mg/kg/day(n=156)
orplacebo(n=70)for8 weeks(StudyPeriodII).Attheend
of 8 weeks, ODD non-remitters (score[9 on the SNAP-IV
ODD subscale and CGI-I[2) with atomoxetine plasma
concentration\800 ng/ml at 2 weeks were re-randomized
to either atomoxetine 1.2 mg/kg/day or 2.4 mg/kg/day for
an additional 4 weeks (Study Period III). ODD remitters
and non-remitters with plasma atomoxetine C800 ng/ml
remained on 1.2 mg/kg/day atomoxetine for 4 weeks.
Patients whoreceived atomoxetine, completed Study Period
II, and entered Study Period III were included in these
analyses. All the groups demonstrated improvement on the
SNAP-IVODDandADHD-combinedsubscales(P\.001).
At the end of Study Periods II and III, ODD and ADHD
improvement was signiﬁcantly greater in the remitter
group compared with the non-remitter groups. Symptom
improvement was numerically greater in the non-remitter
(2.4 mg/kg/day compared with the non-remitter 1.2 mg/kg/
day) group. Atomoxetine plasma concentration was not
indicative of ODD and ADHD improvement after 12 weeks
oftreatment.ADHDandODDsymptomsimprovedinallthe
groupswithlongerdurationonatomoxetine.Resultssuggest
atomoxetine plasma concentration does not predict ODD
and ADHD symptom improvement. However, a higher
atomoxetine dose may beneﬁt some patients.
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Introduction
Attention-Deﬁcit/Hyperactivity Disorder (ADHD) is
among the most common neuropsychiatric disorders in
childhood and adolescence. The prevalence rates of ADHD
in the general population of 6–12-year olds range from 4 to
12% (Brown et al. 2001). Up to 65% of children with
ADHD may have one or more comorbid conditions
(Goldman et al. 1998). Oppositional deﬁant disorder (ODD)
commonly co-occurs with ADHD, and this comorbid group
often experiences severe functional impairment (Gadow
and Nolan 2002; Drabick et al. 2004). Children with ADHD
comorbid with ODD tend to have more severe ADHD
symptoms, and family distress, and peer problems when
compared with children with ADHD alone (Kuhne et al.
1997).
Atomoxetine, a potent and selective norepinephrine
reuptake inhibitor, is used for the treatment of ADHD in
children, adolescents and adults. A recent study that
examined atomoxetine in pediatric patients aged 6–12 years
demonstrated that in patients with ADHD and ODD, treat-
ment with atomoxetine resulted in a signiﬁcant improve-
ment in ADHD symptoms and global clinical functioning
(Bangs et al. 2008).
The bioavailability and clearance of atomoxetine is
inﬂuenced by the activity of the polymorphically expressed
enzyme cytochrome P450 2D6 (CYP2D6) (Sauer et al.
2005). The plasma half-life of atomoxetine ranges from
5.2 h [extensive metabolizers (EM)] to 21.6 h (poor
metabolizers [PM]), depending on the CYP2D6 phenotype.
In CYP2D6 EM, atomoxetine clearance can be reduced by
selective CYP2D6 inhibitors (Sauer et al. 2005). When
taking atomoxetine doses up to 1.8 mg/kg, CYP2D6 PM
are likely to show greater efﬁcacy, an increase in cardio-
vascular tone, and are somewhat more likely to experience
adverse events than EM (Michelson et al. 2007). Since
atomoxetine is a relatively new medication, whether par-
ticular plasma concentrations might predict level of clinical
response is of interest.
In this report, we describe a secondary analysis of a
previously published study (Bangs et al. 2008) that asses-
sed the efﬁcacy of atomoxetine in treating symptoms of
ODD in children with ADHD and comorbid ODD. The
objective of this report is to examine whether atomoxetine
plasma concentration predicts symptom response in those
patients with ADHD and comorbid ODD, including whe-
ther increasing dose is associated with improving response
for those who have not fully responded to the usual rec-
ommended atomoxetine daily dose.
Materials and methods
The details for the methods used in this international mul-
ticenter clinical study are described in a previous publica-
tion (Bangs et al. 2008). Patients were aged 6–12 years and
met Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV) diagnostic criteria for ADHD
(hyperactive/impulsive, inattentive, or combined type) and
comorbid ODD as determined by clinician assessment,
structured clinical interview [Kiddie Schedule for Affective
Disorders and Schizophrenia for School Aged Children-
Present and Lifetime Version (K-SADS-PL)] (Kaufman
et al. 1997), ADHD rating scale, Swanson, Nolan, and
Pelham Rating Scale-Revised (SNAP-IV), (Swanson et al.
2001) score above age and gender norms, Clinical Global
Impressions-Severity (CGI-S) (Guy 1976; National Insti-
tute of Mental Health 1985) score C4, and SNAP-IV ODD
scores of C15.
Patients with a history of bipolar I or II disorder, psy-
chosis, or pervasive developmental disorder were excluded,
as were those with a current diagnosis of major depressive
disorder, post-traumatic stress disorder, patients with a
Children’s Depression Rating Scale-Revised (CDRS-R)
(Poznanski et al. 1996) total raw score [40, serious sui-
cidal risk, history of any seizure disorder (other than febrile
seizures), history of alcohol or other drug abuse within the
past three months, current cardiovascular disease or other
disorders that could be aggravated by increased blood
pressure or heart rate, or those who were likely to need
psychotropic medications other than atomoxetine during
study participation. Additional exclusion criteria details are
described in Bangs et al. (2008).
Efﬁcacy measures included the investigator-rated
SNAP-IV ODD as well as SNAP-IV ADHD-combined
subscales. The SNAP-IV ODD subscale and the SNAP-IV
ADHD combined subscale scores were used to measure
changes in symptoms of ODD and ADHD. For the analyses
reported here, the SNAP-IV ADHD combined subscale
scores (total 18 items including both inattention and
impulsivity/hyperactivity subscales) and the SNAP-IV
ODD subscale scores (total eight items) were evaluated.
The CGI-Improvement (CGI-I) scale is a single-item, cli-
nician rating of the total improvement (or worsening) of the
patient’s symptoms since the beginning of treatment. The
CGI-I, as used in this study, was a composite impression of
ADHD and ODD symptoms. Improvement was rated on a
7-point scale (1 = very much improved; 7 = very much
worsened).
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123After a 3–28-day screening and washout period (Study
Period I), 226 patients met entry criteria and were ran-
domized in a 2:1 ratio to receive double-blind treatment
with atomoxetine 1.2 mg/kg/day or placebo for approxi-
mately 8 weeks (Study Period II). At Visit 3, after
2 weeks on atomoxetine at a dose of 1.2 mg/kg/day,
patients had blood drawn for atomoxetine plasma con-
centration. For the blood draw, patients were instructed to
hold the morning dose of atomoxetine on the day of Visit
3 and were instructed not to eat anything for at least an
hour before their scheduled visit. The patients took their
usual dose of study drug in the presence of a member of
the investigative staff, and the blood samples were
obtained between 60 and 90 min after the patients had
taken atomoxetine. Each patient’s atomoxetine plasma
concentration results determined their Study Period III
(4 weeks) treatment options. In this study, ODD non-
remitters were deﬁned by a score of[9o nt h eS N A P - I V
O D Ds u b s c a l ea n das c o r eo f[2 on the CGI-I, regardless
of their steady-state plasma concentration. At the end of
Study Period III, all the patients had blood drawn to
determine their peak atomoxetine plasma concentration
levels.
The purpose of this study was to assess whether plasma
levels at Week 2 or Week 12 were predictive of ADHD and
ODD symptom improvement. The measures used were the
SNAP-IV ODD subscale scores, the SNAP-IV ADHD
combined subscale scores, and the CGI-I at the end of the
Study Period II or at the end of the Study Period III.
A blood sample was drawn at the beginning of the study
period to determine cytochrome P450 2D6 (CYP2D6)
genotype. Adverse events were collected by open-ended
discussion at all the visits.
For the purpose of this study, in order to examine if
atomoxetine plasma concentration at steady state (Week 2)
would predict efﬁcacy outcomes, all the 132 male and
female patients who were treated with atomoxetine 1.2 mg/
kg/day and who completed the acute 8-week treatment
phase were included in these analyses. Patients were
grouped by their dose in Study Period III and ODD remitter
status at the end of Study Period II. Subgroups were
deﬁned by ODD remitter status at the end of Study Period
II. One subgroup comprised 46 patients who were non-
remitters and received an increased dose of atomoxetine
2.4 mg/kg/day during the additional 4 weeks of treatment
(Study Period III). The second subgroup comprised the 69
patients who met non-remitter criteria for ODD symptom
reduction and remained on atomoxetine 1.2 mg/kg/day
during the additional 4 weeks of treatment. The third
subgroup comprised 17 patients who were ODD remitters
and remained on atomoxetine 1.2 mg/kg/day. Patients who
were administered placebo during Study Period II were not
included in these analyses.
Bioanalytical method
Human plasma samples obtained during this study were
analyzed at SFBC Taylor, located in Princeton, NJ, USA.
The samples were analyzed for atomoxetine using a vali-
dated LC/APCI/MS/MS method. The lower limit of
quantiﬁcation was 2.50 ng/ml. Samples above the limit of
quantiﬁcation were diluted and reanalyzed to yield results
within the calibrated range. The inter-assay accuracy (%
relative error) during validation ranged from -6.05 to
-3.20%, and the inter-assay precision (% relative standard
deviation) during validation ranged from 1.37 to 6.20%.
Atomoxetine was stable for up to 15 months when stored at
approximately -70C.
Statistical analyses
The relationships between atomoxetine plasma concentra-
tion (both Week 2 and Week 12) and ADHD or ODD
symptoms were examined by regression analyses using the
atomoxetine plasma concentration as a predictor and the
ADHD or ODD symptoms as response variables for Study
Periods II and III.
Frequency data were analyzed using the Fisher–Free-
man–Halton test for three-way frequencies, and Fisher’s
exact test for the two-way comparisons.
Unless otherwise noted, continuous data were analyzed
using the analysis of variance (ANOVA) model with the
term for treatment groups. Baseline was deﬁned as the last
available score at Visit 1 or Visit 2.
Analysis of the SNAP-IV subscales was conducted
using the analysis of covariance (ANCOVA) model on the
last-observation-carried-forward (LOCF) change from
baseline to endpoint for Study Periods II and III (up to
Week 12). The ANCOVA model included terms of base-
line, treatment groups, and investigator. Tests were eval-
uated based on a two-sided signiﬁcance level of 0.05.
Multiplicity was not adjusted since this analysis was
exploratory. Throughout the manuscript, the term ‘‘signif-
icant’’ denotes ‘‘statistical signiﬁcance’’ unless otherwise
speciﬁed.
Results
Baseline demographics and other variables
The demographic characteristics for the three subgroups
(Table 1) showed that the majority of patients were male,
Caucasian, had ADHD combined subtype, did not have a
family history of ADHD, had previous stimulant use, and
had an extensive metabolizer (EM) CYP2D6 genotype.
The overall mean age range was 9.26–10.40 years. The
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123mean age of the non-remitter 2.4 mg/kg/day group was
signiﬁcantly lower than the remitter 1.2 mg/kg/day group
(P = .035). The non-remitter 2.4 mg/kg/day group had
signiﬁcantly more male patients (100%) than the non-
remitter 1.2 mg/kg/day group [89.86% (P = .041)].
At study entry, patients in the Study Period III ODD
remitter 1.2 mg/kg/day group were signiﬁcantly taller and
weighed more than patients in the non-remitter 2.4 mg/kg/
day and non-remitter 1.2 mg/kg/day groups; while height
and weight were not signiﬁcantly different between the
non-remitter groups. There were 16 patients in the non-
remitter 1.2 mg/kg/day group with plasma concentrations
[800 ng/ml at Week 2.
There were no signiﬁcant differences between the three
subgroups as regards reasons for discontinuation from the
study (Table 2).
The baseline mean SNAP-IV ADHD combined and
ODD subscale scores were similar with no signiﬁcant
differences among groups (Table 3). These scores indicate
moderate disease severity.
Symptom ratings and atomoxetine plasma
concentrations
In Study Period II, after 2 weeks of treatment with ato-
moxetine 1.2 mg/kg/day, mean atomoxetine plasma
Table 1 Patient baseline characteristics
Event Non-remitter atomoxetine
2.4 mg/kg/day (N = 46)
Non-remitter atomoxetine
1.2 mg/kg/day (N = 69)
Remitter atomoxetine
1.2 mg/kg/day (N = 17)
Total
(N = 132)
Age, yr mean (SD)*
a 9.3 (1.9) 9.7 (1.7) 10.4 (1.8) n/a
Gender, n (%)*
a
Female 0 (0.0) 7 (10.1) 2 (11.8) 9 (6.8)
Male*
b 46 (100.0) 62 (89.9) 15 (88.2) 123 (93.2)
DSM-IV ADHD subtype, n (%)
Hyperactive 1 (2.2) 6 (8.7) 0 (0.0) 7 (5.3)
Inattentive 5 (10.9) 8 (11.6) 0 (0.0) 13 (9.9)
Combined 40 (87.0) 55 (79.7) 17 (100) 112 (84.9)
Weight, kg mean (SD)***
a,***
c 32.0 (8.1) 33.7 (8.7) 41.8 (8.0) 34.1 (8.9)
Height, cm mean (SD)**
a,*
c 135.0 (11.9) 137.6 (11.0) 144.2 (9.9) 137.6 (11.5)
Previous stimulant use, n (%)
No 15 (32.6) 23 (33.3) 4 (23.5) 42 (31.8)
Yes 31 (67.4) 46 (66.7) 13 (76.5) 90 (68.2)
Metabolizer type, n (%)
d
Extensive metabolizer 46 (100.0) 66 (97.1) 15 (88.2) 127 (97.0)
Poor metabolizer 0 (0.0) 2 (2.9) 2 (11.8) 4 (3.1)
Origin, n (%)
Caucasian 41 (89.1) 67 (97.1) 17 (100.0) 125 (94.7)
Hispanic 2 (4.4) 0 (0.0) 0 (0.0) 2 (1.5)
Other 3 (6.5) 2 (2.9) 0 (0.0) 5 (3.8)
No family history ADHD, n (%)
Mother 42 (91.3) 66 (95.7) 17 (100.0) 125 (94.7)
Father 39 (84.8) 55 (79.7) 16 (94.1) 110 (83.3)
Grandparent 39 (84.8) 57 (82.6) 17 (100.0) 113 (85.6)
Siblings 35 (76.1) 51 (73.9) 16 (94.1) 102 (77.3)
n/a not applicable, SD standard deviation, DSM-IV diagnostic and statistical manual of mental disorders, fourth edition, ADHD attention-deﬁcit/
hyperactivity disorder
* P\.05, ** P\.01, *** P\.001
a Non-remitter atomoxetine 2.4 mg/kg/day versus remitter atomoxetine 1.2 mg/kg/day
b Non-Remitter Atomoxetine 2.4 mg/kg/day versus non-remitter atomoxetine 1.2 mg/kg/day
c Non-remitter atomoxetine 1.2 mg/kg/day versus remitter atomoxetine 1.2 mg/kg/day
d n=68 for non-remitter atomoxetine 1.2 mg/kg/day group
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123concentrations (steady state) were signiﬁcantly lower for
patients who were designated in Study Period III as the
ODD non-remitter 2.4 mg/kg/day group (n=46) as com-
pared with either the non-remitter 1.2 mg/kg/day group
(n=69, P\.001), or the remitter 1.2 mg/kg/day group
(n=17, P = .002). No signiﬁcant differences were seen
between the non-remitter 1.2 mg/kg/day and the remitter
1.2 mg/kg/day groups (n=17, P = .062]) at Week 2
(Table 4). After 12 weeks of atomoxetine treatment (end of
Study Period III), Week 2 plasma concentrations did not
signiﬁcantly predict ADHD and ODD outcomes for any
group using regression analysis. Furthermore, Week 12
plasma levels did not predict end of study ADHD or ODD
outcomes for any group using regression analysis (data not
shown).
Table 4 displays atomoxetine mean plasma concentra-
tionsforallthethreegroupsatWeeks2and12.Atomoxetine
plasma concentration at Week 12 for the non-remitter
2.4 mg/kg/day group was signiﬁcantly greater compared to
thenon-remitter1.2 mg/kg/daygroup(P\.001).However,
at Week 12, the non-remitter 2.4 mg/kg/day group did not
demonstrate signiﬁcantly greater improvement compared
Table 2 Primary reason for study discontinuation
Primary reason for discontinuation
a Non-remitter atomoxetine
2.4 mg/kg/day
[N = 46, n (%)]
Non-remitter atomoxetine
1.2 mg/kg/day
[N = 69, n (%)]
Remitter atomoxetine
1.2 mg/kg/day
[N = 17, n (%)]
Total
[N = 132,
n (%)]
Adverse event 2 (4.3) 0 (0.0) 0 (0.0) 2 (1.5)
Lack of efﬁcacy (patient and physician
perception)
3 (6.5) 4 (5.8) 0 (0.0) 7 (5.3)
Lack of efﬁcacy (patient perception) 0 (0.0) 2 (2.9) 0 (0.0) 2 (1.5)
Personal conﬂict or other patient
decision
1 (2.2) 0 (0.0) 0 (0.0) 1 (0.8)
Unable to contact patients/caregiver 0 (0.0) 1 (1.4) 0 (0.0) 1 (0.8)
a There were no signiﬁcant differences across or between any groups
Table 3 SNAP-IV ADHD combined subscale and ODD subscale baseline scores (Visit 1 and Visit 2; pre-atomoxetine treatment), mean change
from baseline scores, and CGI-I scores by Study Period III ODD response group status
Scale and ODD response group N = 132
(n)
Baseline
a
mean (SD)
Week 2 (steady state) change
from baseline mean (SD)
Week 8
b change from
baseline mean (SD)
Week 12
c change from
baseline mean (SD)
SNAP-IV ADHD combined subscale
Non-remitter (2.4) 46 45.2 (5.4) -8.7 (10.0) -10.3 (8.8) -14.3 (11.0)
Non-remitter (1.2) 69 44.2 (7.4) -5.6 (9.6) -6.4 (9.4) -10.9 (10.3)
Remitter (1.2) 17 44.3 (4.8) -16.5 (8.4) -28.7 (9.3) -26.4 (14.2)
SNAP-IV ODD subscale
Non-remitter (2.4) 46 18.9 (2.7) -4.1 (5.0) -3.2 (4.1) -5.5 (5.5)
Non-remitter (1.2) 69 19.0 (2.2) -3.1 (5.0) -2.1 (4.4) -4.4 (5.1)
Remitter (1.2) 17 18.1 (1.8) -6.8 (5.0) -12.9 (2.3) -9.5 (6.2)
CGI-I
d
Non-remitter (2.4) 46
d 3.4 (1.0) 3.4 (1.2) 2.9 (1.0)
Non-remitter (1.2) 69
d 3.8 (1.3) 3.8 (1.3) 3.2 (1.3)
Remitter (1.2) 17
d 2.7 (1.1) 1.5 (0.5) 2.0 (1.3)
SNAP-IV Swanson, Nolan, and Pelham rating scale-revised, ADHD attention-deﬁcit/hyperactivity disorder, ODD oppositional deﬁant disorder,
CGI-I clinical global impression-improvement, SD standard deviation
a There were no signiﬁcant differences across or between any groups at baseline
b End of Study Period II, all the patients on atomoxetine 1.2 mg/kg/day; rerandomized at Week 8 to 1.2 mg/kg/day or 2.4 mg/kg/day
atomoxetine
c End of Study Period III, patient subgroups (ODD response group status) on same dose of 1.2 mg/kg/day or higher dose of 2.4 mg/kg/day for
4 weeks
d No baseline score for this scale
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123with the non-remitter 1.2 mg/kg/day group on the SNAP-IV
ADHD subscale score (P = .050), the SNAP-IV ODD
subscale score, or the CGI-I score (Table 3). Atomoxetine
plasmaconcentrationatWeek12inthenon-remitter2.4 mg/
kg/day group was not signiﬁcantly different from the
remitter 1.2 mg/kg/day group. Similarly, the atomoxetine
plasma concentration of the non-remitter 1.2 mg/kg/day
group at Week 12 was not signiﬁcantly different from the
remitter 1.2 mg/kg/day group.
Table 3 demonstrates the mean change from baseline to
Weeks 2, 8, and 12 for the SNAP-IV ADHD combined sub-
scale scores and the SNAP-IV ODD subscale scores. The
CGI-I scores at Weeks 2, 8, and 12 are also shown. The
remitter 1.2 mg/kg/day group demonstrated signiﬁcantly
greaterADHDsymptomimprovementfrombaselinetoWeek
12 on the SNAP-IV ADHD combined subscale score
(P = .024), and the CGI-I score (P = .008) compared with
the non-remitter 2.4 mg/kg/day group, and on the SNAP-IV
ADHD combined subscale score (P\.001), the SNAP-IV
ODD subscale score (P = .013), and the CGI-I score
(P = .002) with the non-remitter 1.2 mg/kg/day group
(Table 3).Similar results wereseenwithsigniﬁcantlygreater
improvement in the remitter 1.2 mg/kg/day group from
baseline to Week 8 on the SNAP-IV ADHD combined sub-
scale score (P\.001), the SNAP-IV ODD subscale score
(P\.001), and the CGI-I score (P = .014) compared with
the non-remitter 2.4 mg/kg/day group, and on the SNAP-IV
ADHD combined subscale score (P\.001), the SNAP-IV
ODD subscale score (P\.001) and the CGI-I score
(P\.001) with the non-remitter 1.2 mg/kg/day group.
On the SNAP-IV ADHD-combined subscale scores, the
remitter 1.2 mg/kg/day group experienced signiﬁcant
improvement compared with either non-remitter group,
from baseline to each week displayed in Fig. 1. Similar
results were demonstrated at every visit on the SNAP-IV
ODD subscale with the exception of Week 2 (no signiﬁcant
difference compared with non-remitter 1.2 mg/kg/day
group) and 12 (no signiﬁcant difference compared with
non-remitter 2.4 mg/kg/day group) (Fig. 2).
In both non-remitter groups, there was continuing ODD
and ADHD symptom improvement from Weeks 8 to 12
with longer atomoxetine treatment irrespective of whether
the dose was increased. The non-remitter 2.4 mg/kg/day
group showed a signiﬁcant improvement at Week 8
(P = .014) and Week 10 (P = .033) on the SNAP-IV
ADHD combined subscale compared with the non-remitter
1.2 mg/kg/day group. No signiﬁcant differences between
the non-remitter groups were seen on the SNAP-IV ODD
subscale scores from baseline to Weeks 2, 4, 6, 8, and 12
(all P C .05).
As seen in Fig. 3, at every visit from Weeks 2 to 12
there was a signiﬁcantly greater improvement on the CGI-I
ADHD/ODD score in the remitter 1.2 mg/kg/day group
compared with the non-remitter 2.4 mg/kg/day group or
the non-remitter 1.2 mg/kg/day group. From Weeks 2 to
Table 4 Atomoxetine plasma concentrations (ng/ml) by Study Period III ODD response group status
Study Period III ODD
response group status
Week 2 (steady state) Week 12
N Mean (SD) Median Minimum Maximum N Mean (SD) Median Minimum Maximum
Non-remitter (2.4 mg/kg/day) 41 348.0 (191.4) 351.4 8.5 745.5 42 849.1 (532.3) 741.9 23.9 2403.1
Non-remitter (1.2 mg/kg/day) 60 581.2*** (366.7) 488.8 28.3 1825.0 63 564.0*** (316.9) 527.7 18.4 1331.4
Remitter (1.2 mg/kg/day) 17 873.6** (989.2) 535.8 4.7 3716.9 15 635.5 (411.4) 477.0 128.0 1212.0
Note: Because this study included all the patients who entered Study Period III, patients in the non-remitter 1.2 mg/kg/day atomoxetine group
included patients with steady-state atomoxetine plasma concentration values[800 ng/ml
ODD oppositional deﬁant disorder, SD standard deviation
*** P\.001 non-remitter 2.4 mg/kg/day versus non-remitter 1.2 mg/kg/day
** P\.01 non-remitter 2.4 mg/kg/day versus remitter 1.2 mg/kg/day
Fig. 1 Visitwise mean change from baseline to week on atomoxetine
for SNAP-IV ADHD combined subscale scores (last-observation-
carried-forward) by Study Period III ODD response groups.
aP-value
comparison non-remitteratomoxetine 2.4 mg/kg/day versus Non-remit-
ter atomoxetine 1.2 mg/kg/day,
bP-value comparison non-remitter
atomoxetine 2.4 mg/kg/day versus remitter atomoxetine 1.2 mg/kg/
day,
cP-value comparison non-remitter atomoxetine 1.2 mg/kg/day
versus Remitter atomoxetine 1.2 mg/kg/day; *P\.05; **P\.01;
***P\.001
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12312, there were no signiﬁcant differences in the CGI-I
ADHD/ODD score between the non-remitter groups.
Safety
Therewerenodeathsreportedinanysubgroup.Therewereno
discontinuations due to adverse events (AEs) in the remitter
1.2 mg/kg/day group or the non-remitter 1.2 mg/kg/day
group. Two out of 46 patients (4.3%) in the non-remitter
2.4 mg/kg/day group discontinued from the whole study due
toanAE[aspartateaminotransferaseincreased(n=1,2.2%),
tic(n=1,2.2%)].Nopatientsinthenon-remitter1.2 mg/kg/
day group or the remitter 1.2 mg/kg/day group discontinued
during Weeks 8–12.
There were no signiﬁcant differences between treatment
groups in the total number of patients with C1 treatment-
emergent adverse events (TEAEs) (Table 5). There was a
greater incidence (P = .005) of nasopharyngitis in the non-
remitter 2.4 mg/kg/day group (n=12, 26.09%) compared
with the non-remitter 1.2 mg/kg/day group (n=4, 5.80%).
Abdominal pain occurred with greater incidence (P = .048)
in the non-remitter 1.2 mg/kg/day group (n=10, 14.49%)
compared with the non-remitter 2.4 mg/kg/day group
(n=1,2.17%).Therewasagreaterincidence(P = .028)of
vomiting in the remitter 1.2 mg/kg/day group (n=6,
35.29%) compared with the non-remitter 1.2 mg/kg/day
group (n=8, 11.59%).
Discussion
The ﬁndings of this study suggest that although some
patients may beneﬁt from higher atomoxetine plasma
concentrations, exposure alone may not be indicative of
therapeutic outcome for ADHD or ODD symptoms in
children with ADHD and comorbid ODD. Using the same
study population, Bangs et al. (2008) previously reported
that ADHD and comorbid ODD patients who did not
achieve adequate ODD symptom reduction after 8 weeks
on atomoxetine 1.2 mg/kg/day and who also had lower
steady-state atomoxetine plasma concentrations (\800
ng/ml) at Week 2 did not beneﬁt from 4 more weeks on
atomoxetine even at a doubled dose. Although this retro-
spective analysis of non-remitters included all the patients
regardless of their Week 2 atomoxetine plasma concen-
tration, analyses found that Week 2 steady-state atomoxe-
tine plasma concentration was not indicative of either ODD
or ADHD symptom improvement. These results were
consistent when comparing Week 2 atomoxetine plasma
concentration at the end of 8 weeks of treatment when all
the patients were on atomoxetine 1.2 mg/kg/day and when
comparing Week 12 atomoxetine plasma concentration
after the non-remitter atomoxetine 2.4 mg/kg/day group
had been on the higher atomoxetine dose for 4 weeks.
These data suggest that other factors are involved in
determining therapeutic response to atomoxetine. In addi-
tion, plasma concentrations at Week 12 also did not predict
therapeutic response in any of the three ODD response
groups.
Perhaps, the most compelling evidence is demonstrated
by the group comparisons for ODD non-remitters. The
non-remitter 2.4 mg/kg/day group was not signiﬁcantly
Fig. 2 Visitwise mean change from baseline to week on atomoxetine
for SNAP-IV ODD combined subscale (mean and SD) scores (last-
observation-carried-forward) by Study Period III ODD response
groups.
aP-value comparison non-remitter atomoxetine 2.4 mg/kg/
day versus remitter atomoxetine 1.2 mg/kg/day,
bP-value comparison
non-remitter atomoxetine 1.2 mg/kg/day versus remitter atomoxetine
1.2 mg/kg/day; *P\.05; **P\.01; ***P\.001
Fig. 3 Clinical global impression––improvement ADHD/ODD vis-
itwise scores by Study Period III ODD remitter groups.
aP-value
comparison non-remitter atomoxetine 2.4 mg/kg/day versus remitter
atomoxetine 1.2 mg/kg/day,
bP-value comparison non-remitter ato-
moxetine 1.2 mg/kg/day versus remitter atomoxetine 1.2 mg/kg/day;
*P\.05; **P\.01; ***P\.001
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Week 2 on the SNAP-IV ADHD subscale, the SNAP-IV
ODD subscale, or the CGI-I where Week 2 atomoxetine
plasma concentrations were signiﬁcantly higher in the non-
remitter 1.2 mg/kg/day group. Further, as demonstrated in
the visitwise ﬁgures for clinical outcomes for ADHD and
ODD, at endpoint and throughout the study, the two ODD
non-remitter groups had similar clinical symptom severi-
ties that did not differ much from Week 2, even though the
2.4 mg/kg/day group had a signiﬁcantly higher atomoxe-
tine plasma concentration at Week 12 compared to the non-
remitter 1.2 mg/kg/day group. Both these ﬁndings suggest
that not responding adequately on ODD symptoms at Week
8 could not have been predicted by plasma concentration
after 2 weeks on treatment.
At Week 2, the remitter 1.2 mg/kg/day group showed
signiﬁcantly greater atomoxetine plasma concentrations
than the non-remitter 2.4 mg/kg/day group but not signif-
icantly different from the non-remitter 1.2 mg/kg/day
group. At Week 12, the atomoxetine plasma concentrations
in the remitter 1.2 mg/kg/day group were not signiﬁcantly
different from either of the ODD non-remitter groups. Yet,
the remitter 1.2 mg/kg/day group demonstrated greater
improvement compared to either non-remitter group on the
SNAP-IV ADHD subscale, SNAP-IV ODD subscale, and
CGI-I at every visit (Figs. 1, 2, 3). Interestingly, the
remitter 1.2 mg/kg/day group demonstrated a worsening of
ADHD and ODD symptoms at Weeks 10 and 12, whereas
both non-remitter groups demonstrated continued or sus-
tained improvement on the SNAP-IV ODD subscale, the
SNAP-IV ADHD subscale and the CGI-I (Figs. 1, 2, 3). In
fact, both non-remitter groups demonstrated continuing
ODD and ADHD symptom improvement from Weeks 8 to
12 with longer atomoxetine treatment irrespective of
whether the dose was increased. It is difﬁcult to interpret
what this means, however, given that longitudinal studies
can show ﬂuctuations in response levels the longer the
study progresses.
Although there have been reported cases suggesting
greater efﬁcacy in treatment of ADHD symptoms with
increased dose or serum levels of atomoxetine, (Michelson
et al. 2007; Paulzen et al. 2008) few studies have examined
whether atomoxetine plasma concentrations would predict
outcome. A study of methylphenidate blood levels and
therapeutic response to ADHD symptom improvement
(Teicher et al. 2006) reported a waxing and waning of
response directly related to higher and lower plasma levels
of methylphenidate, respectively.
However, recent studies have shown no signiﬁcant
improvement in ADHD symptoms using higher doses of
atomoxetine (Kratochvil et al. 2007). Results of two ato-
moxetine dose comparison studies presented together
showed a signiﬁcant reduction in ADHD-RS score in both
studies with no signiﬁcant differences between high dose
(mean atomoxetine dose; 2.49 mg/kg/day and 2.1 mg/kg/
day) and low dose groups (mean atomoxetine dose;
Table 5 Summary of treatment-emergent adverse events with C5% incidence by remitter and treatment subgroup
Adverse event Non-remitter atomoxetine
2.4 mg/kg/day [N = 46, n (%)]
Non-remitter atomoxetine
1.2 mg/kg/day [N = 69, n (%)]
Remitter atomoxetine
1.2 mg/kg/day [N = 17, n (%)]
Total
[N = 132, n (%)]
Patients with C1 TEAE 42 (91.3) 61 (88.4) 13 (76.5) 116 (87.9)
Patients with no TEAE 4 (8.7) 8 (11.6) 4 (23.5) 16 (12.1)
Abdominal pain*
a 1 (2.2) 10 (14.5) 1 (5.9) 12 (9.1)
Abdominal pain upper 8 (17.4) 6 (8.7) 1 (5.9) 15 (11.4)
Anorexia 4 (8.7) 6 (8.7) 2 (11.8) 12 (9.1)
Cough 2 (4.4) 3 (4.4) 2 (11.8) 7 (5.3)
Decreased appetite 13 (28.3) 18 (26.1) 7 (41.2) 38 (28.8)
Fatigue 9 (19.6) 13 (18.8) 4 (23.5) 26 (19.7)
Headache 14 (30.4) 29 (42.0) 7 (41.2) 50 (37.9)
Nasopharyngitis**
b 12 (26.1) 4 (5.8) 1 (5.9) 17 (12.9)
Nausea 8 (17.4) 14 (20.3) 2 (11.8) 24 (18.2)
Pyrexia 1 (2.2) 6 (8.7) 1 (5.9) 8 (6.1)
Vomiting*
c 8 (17.4) 8 (11.6) 6 (35.3) 22 (16.7)
Weight decreased 5 (10.9) 4 (5.8) 3 (17.7) 12 (9.1)
TEAE treatment-emergent adverse event
* P\.05, ** P\.01
a Non-remitter atomoxetine 2.4 mg/kg/day versus non-remitter atomoxetine 1.2 mg/kg/day
b Overall P-value and non-remitter 2.4 mg/kg/day versus non-remitter 1.2 mg/kg/day
c Non-remitter Atomoxetine 1.2 mg/kg/day versus remitter atomoxetine 1.2 mg/kg/day
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1231.58 mg/kg/day, and 1.1 mg/kg/day). Corroborating ﬁnd-
ings were reported in a study comparing atomoxetine
treatment in PM versus EM patients with ADHD (Trzepacz
et al. 2008) when physicians were blinded to the CYP2D6
status of patients and the atomoxetine dose was adjusted
based on ADHD symptom improvement and tolerability,
dose distribution largely overlapped between groups
despite differences in plasma concentration (10-fold higher
steady-state average plasma concentration in PM versus
EM). The higher atomoxetine plasma concentrations in PM
patients may not be predictive of treatment response. It
may be that achieving some minimum cerebrospinal ﬂuid
concentration for effects on the central nervous system
norepinephrine transporter, along with genetic and phar-
macodynamic factors, are more important than plasma
pharmacokinetics.
Indeed, complexities in treatment outcome may be
related to heterogeneous neuropsychiatric impairment
reported in patients with ADHD. A comparison of
atomoxetine-treated ADHD patients who were stimulant-
treatment naive with those who were previously stimulant-
responsive found sustained symptom improvement in both
treatment groups, although the stimulant-naive group
demonstrated a slightly greater response rate (Newcorn
et al. 2007). Recent evidence has shown that transporter
genotype may play a role in variation of treatment out-
come: genotype of the dopamine transporter (DAT1)
played a role in ADHD treatment outcome with methyl-
phenidate (Bellgrove et al. 2005). Further, positron emis-
sion tomography (PET) studies have shown evidence in
non-human primates of a relationship between atomoxetine
dose and norepinephrine (NE) transporter occupancy in
the brain (Seneca et al. 2006). Further PET studies may
elucidate whether a relationship exists between effective
NE transporter occupancy levels and atomoxetine plasma
concentration.
Theﬁndingsofthisstudyarelimitedbyseveralfactors.The
primary study from which these analyses were derived was
designed to evaluate the clinical effect of increased ato-
moxetinedosesonlyinpatientswhowereODDnon-remitters
with steady-state plasma concentrations \800 ng/ml after
2 weeks of atomoxetine treatment regardless of their ADHD
response (Bangs et al. 2008). The objective of this report
was post hoc, and the sample size in some subgroups was
smallandunbalancedbetweengroups.Inaddition,becauseof
the different regrouping of patients for this study, patients
in the atomoxetine non-remitter 2.4 mg/kg/day group all
had steady-state plasma concentrations \800 ng/ml during
Weeks 8–12. The non-remitter and remitter groups treated
withatomoxetine1.2 mg/kg/dayduringWeeks8–12included
patients with plasma concentrations, both less than and
[800 ng/ml.
In conclusion, for patients with ADHD and comorbid
ODD who have an initial inadequate response, plasma
concentration may not be an indicator of outcome and
additional improvements. Clinical implications for treat-
ment efﬁcacy suggest that routine monitoring of ato-
moxetine plasma concentration is probably not necessary
unless there is another reason such as poor adherence being
suspected.
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